Immunotherapeutic approaches have substantially improved the treatment of patients with advanced malignancies. However, most ...

Visos teisės saugomos. © 2024 UAB „Lrytas“. Kopijuoti, dauginti, platinti galima tik gavus raštišką UAB „Lrytas“ sutikimą.

Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles ...

Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of ...

Nonpathogenic E. coli displaying decoy-resistant IL18 demonstrate potent anti-tumor responses and boost CAR-NK cell ...

So-called high-dose flu vaccines are available for older people. The reason: their immune system does not always respond ...

A new book about the effects of nature on our wellbeing has transformative implications for the future of health ...

“When these antigens are not present on a cell anymore, the immune system thinks that something has gone wrong with the cell, ...

Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene ...

For the first time, two College of Medicine cancer researchers have earned state cancer support from the Florida Breast ...

IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast CancerCasitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase ...

The latest funding will support the first clinical trial for CTH-401, the startup’s lead cell therapy product, to treat ovarian cancer.